BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35149548)

  • 1. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
    Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
    Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
    Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
    Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
    Suzuki H; Nagase S; Saito C; Takatsuka A; Nagata M; Honda K; Kaneda Y; Nishiya Y; Honda T; Ishizaka T; Nakamura K; Nakada T; Abe Y; Agatsuma T
    Mol Cancer Ther; 2024 Mar; 23(3):257-271. PubMed ID: 38205802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
    Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
    Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
    Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
    Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
    Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.
    Nagai Y; Oitate M; Shiozawa H; Ando O
    Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors.
    Shin SH; Ju EJ; Park J; Ko EJ; Kwon MR; Lee HW; Son GW; Park YY; Kim YJ; Song SY; Lee S; Seo BS; Song JA; Lim S; Jung D; Kim S; Lee H; Park SS; Jeong SY; Choi EK
    Cancer Cell Int; 2023 Aug; 23(1):172. PubMed ID: 37596639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
    Kendsersky NM; Lindsay J; Kolb EA; Smith MA; Teicher BA; Erickson SW; Earley EJ; Mosse YP; Martinez D; Pogoriler J; Krytska K; Patel K; Groff D; Tsang M; Ghilu S; Wang Y; Seaman S; Feng Y; Croix BS; Gorlick R; Kurmasheva R; Houghton PJ; Maris JM
    Clin Cancer Res; 2021 May; 27(10):2938-2946. PubMed ID: 33619171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
    Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology.
    Ogitani Y; Abe Y; Iguchi T; Yamaguchi J; Terauchi T; Kitamura M; Goto K; Goto M; Oitate M; Yukinaga H; Yabe Y; Nakada T; Masuda T; Morita K; Agatsuma T
    Bioorg Med Chem Lett; 2016 Oct; 26(20):5069-5072. PubMed ID: 27599744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma.
    Mao Y; Wei D; Fu F; Wang H; Sun Z; Huang Z; Wang Y; Zhang G; Zhang X; Jiang B; Chen H
    Eur J Med Chem; 2023 Sep; 257():115489. PubMed ID: 37235999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
    Iida K; Abdelhamid Ahmed AH; Nagatsuma AK; Shibutani T; Yasuda S; Kitamura M; Hattori C; Abe M; Hasegawa J; Iguchi T; Karibe T; Nakada T; Inaki K; Kamei R; Abe Y; Nomura T; Andersen JL; Santagata S; Hemming ML; George S; Doi T; Ochiai A; Demetri GD; Agatsuma T
    Cancer Discov; 2021 Jun; 11(6):1508-1523. PubMed ID: 33579785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
    Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
    Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.